Biogen Message Board - Msg: 4028184

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 164.81

-1.7%

Nov 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michelino who wrote (638)	4/10/1998 5:19:00 PM
From: Stanley Cowen	Read Replies (2) of 1686

Local paper reported positive results from yearlong study at University of of Miami's Center for Liver Diseases of Amgen's Infergen on Hepatitis C patients. Results reported in journal Hepatology April issue. According to Lynn Henderson, Amgen spokesperson, conventional therapy consisted of a lower dose of Infergen and Intron A, a drug made by Schering Plough and licensed by Biogen. Under this therapy, only half of the patients responded to the low dose therapy and only 20 period achieved remission. When the dose of infergen dosage was increased, nearly 60 percent of those who initially responded but relapsed, successfully achieved a sustained remission. Royalties from Intron A may be impacted. Has this hurt the stock price? Any comments from persons with better understanding of the situation would be appreciated. Thanks Stan P.S. Support at 41, Resistance at 49.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next